Business
New Contract with SFA Therapeutics
New Contract with SFA Therapeutics.
About this update from Hvivo Plc
[{"type":"text","content":"\n \nRNS Number : 2351X Open Orphan PLC 18 December 2019 \n\n18 December 2019\nOpen Orphan plc\n(\"Open Orphan\" or the \"Company\")\n New Contract with SFA Therapeutics\n \nOpen Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce the signing of a contract with SFA Therapeutics, a biopharmaceutical company based in Pennsylvania, USA (\"SFA Therapeutics\"). \nThis contract sees Venn Life Sciences (\"Venn\"), part of Open Orphan plc, provide SFA Therapeutics with assistance in the filing of a European Medicines Agency application for Orphan Drug Designation including providing both consulting and regulatory writing services. Open Orphan is delighted to support SFA Therapeutics in the development of its promising novel treatment and it is hoped that this agreement will be the first step in a longer-term relationship between both companies.\nThe contract is evidence of Open Orphan executing upon its strategy of winning contracts in the fast-growing orphan drug sector and its capability in being able to assist North American companies with their European activities. It is also an important contract as it is the first time that Venn has utilised Open Orphan's skills and expertise in filing a European Medicines Agency Orphan Drug Designation for a North American company which already has a US FDA Orphan Drug Designation.\nCathal Friel, Chief Executive of Open Orphan commented:\n\"This contract is a further demonstration of delivery against one of Open Orphan's key objectives, transforming Venn. The contract is an exciting one as we are now building on our capability by actively winning work in the fast-growing orphan drug sector. We look forward to delivering the contract for SFA Therapeutics and building upon the relationship.\"\n \nEnquiries:\nOpen Orphan plc Tel: +353 1 644 0007\nCathal Friel, Chief Executive Officer\nArden Partners (Nominated Adviser and Joint Broker) Tel: +44 (0)20 7614 5900\nJohn Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer\nDavy (Euronext Growth Adviser and Joint Broker) Tel: +353 (0)1 679 6363\nAnthony Farrell (Corporate Finance)\nCamarco (Financial PR) Tel: +44 (0)20 3757 4980\nTom Huddart / Dan Sherwen\n \nNotes to Editors on Open Orphan:\nOpen Orphan plc is a European-focused, rare and orphan dr...